Strategies of Targeting Tumors and Cancers
DOI:
https://doi.org/10.6000/1929-2279.2012.01.01.19Keywords:
Cancer, Targeted Therapy, Tumors, Drug Targeting, Chemotherapy.Abstract
Targeted cancer therapies use drugs that specially reach at the affected site block the growth and spread of cancer. They interfere with specific molecules involved in carcinogenesis (the process by which normal cells become cancer cells) and tumor growth. By focusing on molecular and cellular changes that are specific to cancer, targeted cancer therapies may be more effective than current treatments and less harmful to normal cells. Targeted cancer therapies interfere with cancer cell growth and division in different ways and at various points during the development, growth, and spread of cancer.
The present article provides an overview of various aspects of cancers and tumors that include causes of the diseases and their underlying biology, existing methods of treatment, major strategies of cancer and tumor targeting and mechanisms of their mode of actions. The review article also presents a current state-of -the art of the cancer targeting approaches and discusses various types of advanced targeting techniques like pH, temperature and magnetic targeting. A brief account of recent literature pertaining to cancer targeting is also discussed.
References
World Health Organization: Cancer. /http://www.who.int/cancer/enS. Accessed 2007, February.
Papac RJ. Origins of Cancer. Yale J Biol Med 2001; 74: 391-8.
Dinauer N, Balthasar S, Weber C, Kreuter J, Langer K, Von Briesen H. Selective targeting. Biomaterials 2005; 26: 5898-906. http://dx.doi.org/10.1016/j.biomaterials.2005.02.038
Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer. Adv Drug Del Rev 2002; 54(5): 631-51. http://dx.doi.org/10.1016/S0169-409X(02)00044-3
Leroux JC, Cozens R, Roesel JL, et al. Pharmacokinetics of a novel. J Pharm Sci 1995; 84: 1387-91. http://dx.doi.org/10.1002/jps.2600841202
Weinberg RA. The biology of cancer. New York, NY: Garland Science; Taylor & Francis Group, LLC, 2007.
Klein CA. Cancer. The metastasis cascadeScience. (New York, N.Y.). 2008; 321(5897): 1785-7.
Vogelstein B, Kinzler KW. The Genetic Basis of Human Cancer. McGraw–Hill, 1998.
Kinzler KW, Vogelstein B. The genetic basis of human cancer. 2nd revised ed., New York: McGraw-Hill, Medical Pub. Division 2002; p. 5.
Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997; 386: 761-3. http://dx.doi.org/10.1038/386761a0
Todd R, Wong DT. Oncogenes. Anticancer Res 1999; 19 (6A): 4729-46.
Croce, C. M. Oncogenes and Cancer. N Engl J Med 2008; 358(5): 502-11. http://dx.doi.org/10.1056/NEJMra072367
Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance. Nat Rev Cancer 2003; 3: 695-701. http://dx.doi.org/10.1038/nrc1165
Sieber OM, Heinimann K, Tomlinson IP. Genomic instability. Nat Rev Cancer 2003; 3: 701-8. http://dx.doi.org/10.1038/nrc1170
Beckman Robert A, Loeb Lawrence A. Genetic instability. Semin Cancer Biol 2005; 15: 423-35.
Bissell MJ, Radisky D. Putting tumours. Nat Rev Cancer 2001; 1: 46-54. http://dx.doi.org/10.1038/35094059
Barcellos-Hoff MH, Medina Daniel. New highlights. Breast Cancer Res 2005; 7(1): 33-6. http://dx.doi.org/10.1186/bcr972
Fallon JH, Seroogy KB, Loughlin SE, et al. Epidermal growth. Science 1984; 224(4653): 1107-9. http://dx.doi.org/10.1126/science.6144184
Boveri T. Zur Frage der Entstehung maligner Tumoren Gustav Fischer, 1914. English translation: The origin of malignant tumors by Boveri, M. Williams and Wilkins, 1929.
Muller HJ. Artificial Transmutation. Science 1927; 46: 84-7. http://dx.doi.org/10.1126/science.66.1699.84
Knudson AG. Two genetic. Nat Rev Cancer 2001; 1: 157-62. http://dx.doi.org/10.1038/35101031
Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability. Trends Cell Biol 1999; 9: M57-M60. http://dx.doi.org/10.1016/S0962-8924(99)01661-X
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. http://dx.doi.org/10.1016/S0092-8674(00)81683-9
Kendall SD, Linardic CM, Adam SJ, Counter CM. Genetic Modeling. Cancer Res 2005; 65: 9824-28. http://dx.doi.org/10.1158/0008-5472.CAN-05-1543
Wulfkuhle JD, Liotta LA, Ptrioin EF. Proteomic Applications. Cancer 2003; 3: 267-275.
Blixt O, Bueti D, Burford B, et al. Autoantibodies to aberrantly. Breast Cancer Res 2011; 13(R25): 1-16. http://breast-cancer-research.com/content/13/2/R25
Cohen S, Margel S. Engineering of near IR. J Nanobiotechno 2012; 10(36): 1-20. http://dx.doi.org/10.1186/1477-3155-10-36
Wu A, Ou P, Zeng L. Biomedical Applications. NANA: brief Reports and Rev 2010: 5: 245-270.
Xian Y, Wang J. Superparamagnetic iron oxide. Quant Imaging MedSurg 2011; 1: 35- 40.
Zhang L, Yu FQ, Cole AJ, Chertok B, David AE, Wang JK, Yan VC. AAPS J 2009; 11: 693-702. http://dx.doi.org/10.1208/s12248-009-9151-y
Takimoto CH, Calvo E. Principles of Oncologic Pharmacotherapy in Pazdur, R, Wagman LD, Camphausen KA, Hoskins WJ, (Eds) 11 ed. Cancer Management: A Multidisciplinary Approach. 2008
Petrovski A, Mccall J. Multi-objective Optimisation of Cancer Chemotherapy Using Evolutionary Algorithms. In EMO '01: Proceedings of the First International Conference on Evolutionary Multi-Criterion Optimization, Springer-Verlag, London, UK, 2001; pp. 531-45. http://dx.doi.org/10.1007/3-540-44719-9_37
Wheldon T. 4th edn. ed. Mathematical Models in Cancer Research. Adam Hilger, Bristol, Philadelphia, 1988.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative Chemotherapy. N Engl J Med 2006; 355: 11-20. http://dx.doi.org/10.1056/NEJMoa055531
Fassoulaki A, Triga A, Melemeni A, Sarantopoulos C. Multimodal Analgesia. Anesth Analg 2005; 101: 1427-32. http://dx.doi.org/10.1213/01.ANE.0000180200.11626.8E
Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive Toxicity. J Clin Oncol 2006; 24(30): 4833-39. http://dx.doi.org/10.1200/JCO.2006.07.5937
Triesscheijn M, Baas P, Schellens JH, Stewart FA. Photodynamic therapy. Oncologist 2006; 11: 1034-44. http://dx.doi.org/10.1634/theoncologist.11-9-1034
Castano AP, Mroz P, Hamblin MR. Photodynamic therapy. Nat Rev Cancer 2006; 6: 535-45. http://dx.doi.org/10.1038/nrc1894
Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Determination of. Photochem Photobiol 2006; 82: 412-417. http://dx.doi.org/10.1562/2005-12-14-RA-754
Hirsch LR, Gobin AM, Lowery AR, et al. Metal nanoshells. Ann Biomed Eng 2006; 34:15-22. http://dx.doi.org/10.1007/s10439-005-9001-8
Shi X, Wang S, Sun H, Baker Jr JR. Improved biocompatibility. Soft Matter 2007; 3: 71-74. http://dx.doi.org/10.1039/b612972b
US Food and Drug Administration, Office of Combination Products (2003) Annual Report to Congress Federal Food, Drug, and Cosmetic Act as Amended by the Medical Device User Fee Act of 2002, National Press Office, Rockville, MD.
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as. Nat Nanotechno 2007; 2: 751-60. http://dx.doi.org/10.1038/nnano.2007.387
Duncan R. Polymer conjugates. Nat Rev Cancer 2006; 6: 688-701. http://dx.doi.org/10.1038/nrc1958
Sofou S. Surface-active. Nanomed 2007; 2: 711-24. http://dx.doi.org/10.2217/17435889.2.5.711
Basarkar A, Singh J, Nanoparticulate systems. Int J Nanomed 2007; 2: 353-60.
Boyd BJ. Past and future. Exp Opin Drug Deliv 2008; 5: 69-85. http://dx.doi.org/10.1517/17425247.5.1.69
Huang H, Pierstorff E, Osawa E, Ho D. Active Nanodiamond. Nano Lett 2007; 7: 3305-14. http://dx.doi.org/10.1021/nl071521o
Jiang W, Kim BY, Rutka JT, Chan WC. Advances and. Exp Opin Drug Deliv 2007; 4: 621-33. http://dx.doi.org/10.1517/17425247.4.6.621
Boulikas T, Mylonakis N, Sarikos G, et al. ASCO Annual Meeting Proceedings Part I.; Lipoplatin plus gemcitabine versus cisplatin plus gemcitabine in NSCLC: Preliminary results of a phase III trial. J Clin Oncol 2007; 25: 18028.
Pirollo KF, Chang EH. Targeted Delivery. Cancer Res 2008; 68(5): 1247-50. http://dx.doi.org/10.1158/0008-5472.CAN-07-5810
Cho K, Wang X. Nie S, Chen Z., Shin DM. Therapeutic Nanoparticles. Clin Cancer Res 2008; 14(5): 1310-16. http://dx.doi.org/10.1158/1078-0432.CCR-07-1441
Wolinsky JB, Grinstaff MW. Therapeutic and. Adv Drug Deliv Rev 2008; 60: 1037-55. http://dx.doi.org/10.1016/j.addr.2008.02.012
Iyer A, Khaled G, Fang J, Maeda H. Exploiting the. Drug Discov Today 2006; 11: 812-18. http://dx.doi.org/10.1016/j.drudis.2006.07.005
Smith AM, Dave S, Nie S, True L, Gao X. Multicolor quantum dots for molecular diagnostics of cancer. Expert Rev Mol Diagn 2006; 6(2): 231-44. http://dx.doi.org/10.1586/14737159.6.2.231
Park JH, Kwon S, Lee M, et al. Self-assembled. Biomaterials 2006; 27: 119-26.
Lijnen HR. Angiogenesis and obesity. Cardiovasc Res 2008; 78(2): 286-93. http://dx.doi.org/10.1093/cvr/cvm007
van Vlerken LE, Duan Z, Seiden MV, Amiji MM. Multidrug resistant. Cancer Res 2007; 67(10): 4843-50. http://dx.doi.org/10.1158/0008-5472.CAN-06-1648
Park JH, Lee S, Kim JH, Park K, Kim K, Kwon I.C. Polymeric nanomedicine. Prog Polym Sci 2008; 33: 113-37. http://dx.doi.org/10.1016/j.progpolymsci.2007.09.003
Park JH, Kwon S, Lee M, et al. Self-assembled. Biomaterials 2006; 27: 119-26.
Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition. Oncogene 2006; 25: 4633-46. http://dx.doi.org/10.1038/sj.onc.1209597
Wang X, Yang L, Chen Z, Shin, DMCA. Application of. J Clin 2008; 58: 97-110.
Deryugina EI, Quigley JP. Matrix metalloproteinases. Cancer Metastasis Rev 2006; 25: 9-34. http://dx.doi.org/10.1007/s10555-006-7886-9
Mansour AM, Drevs J, Esser N, Hamada FM, Badary OA, Unger C, Fichtner I, Kratz F. A new approach. Cancer Res 2003; 63: 4062-66.
Yockman JW, Maheshwari A, Han SO, Kim SW. Tumor regression. J Control Release 2003; 87:177-86. http://dx.doi.org/10.1016/S0168-3659(02)00362-0
Sahoo SK, Ma W, Labhasetwar V. Efficacy of transferrin-conjugated. Int J Cancer 2004; 112: 335-40. http://dx.doi.org/10.1002/ijc.20405
Wagner E. Programmed drug. Exp Opin Biol Ther 2007; 7: 587-93. http://dx.doi.org/10.1517/14712598.7.5.587
Singh R, Lillard Jr JW. Nanoparticle-based. Exp Mole Patho 2009; 86: 215-23. http://dx.doi.org/10.1016/j.yexmp.2008.12.004
Conrad D. Tumor-Seeking Nanoparticles, NCI Alliance for Nanotechnology in Cancer. Monthly Feature, 2006.
McWhirter JR, Kretz-Rommel A, Saven A, et al. Antibodies selected. Proc Natl Acad Sci USA 2006; 103: 1041-46. http://dx.doi.org/10.1073/pnas.0510081103
Krag DN, Shukla GS, Shen GP, et al. Selection of Tumor-binding. Cancer Res 2006; 66(15): 7724-33. http://dx.doi.org/10.1158/0008-5472.CAN-05-4441
Brissette R, Prendergast JK, Goldstein NI. et al. Dentification of cancer. Curr Opin Drug Disc 2006; 9: 363-69.
Lee JH, Yigit MV, Mazumdar D, Lu Y. Molecular diagnostic. Adv Drug Deliv Rev 2010; 62: 592-605. http://dx.doi.org/10.1016/j.addr.2010.03.003
Tuerk C, Gold L. Systematic evolution. Science 1990; 249: 505-10. http://dx.doi.org/10.1126/science.2200121
Ellington AD, Szostak JW. In vitro selection. Nature 1990; 346: 818-22. http://dx.doi.org/10.1038/346818a0
Guo KT, Paul A, Schichor C, Ziemer G, Wendel HP, CELL-SELEX Int J Mol Sci 2008; 9: 668-78. http://dx.doi.org/10.3390/ijms9040668
Xiao Z, Frieder J, Teply BA, Farokhzad OC. Aptamer Conjugates: Emerging Delivery Platforms for Targeted Cancer Therapy in Drug Delivery in Oncology: From Basic Research to Cancer Therapy 2012; 1263-1281.
Nimjee SM, Rusconi CP, Harrington RA, Sullenger BA. The potential of aptamers. Trends Cardiovasc Med 2005; 15: 41-5. http://dx.doi.org/10.1016/j.tcm.2005.01.002
Bagalkot V, Farokhzad OC, Langer R, et al. An Aptamer-Doxorubicin. Angew Chem Int Ed 2006; 45(48): 8149-52. http://dx.doi.org/10.1002/anie.200602251
Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer. Proc Natl Acad Sci USA 2006; 103: 6315-20. http://dx.doi.org/10.1073/pnas.0601755103
Newton JR, Kelly KA, Mahmood U, et al. In vivo selection. Neoplasia 2006; 8: 772-80. http://dx.doi.org/10.1593/neo.06331
Saveanu A, Jaquet P, Gunz G, et al. Somatostatin and Dopamine-Somatostatin. Neuroendocrinology 2006; 83: 258-63. http://dx.doi.org/10.1159/000095536
Leroueil PR, Hong S, Mecke A, et al. The Binding Avidity. Chem Biol 2007; 14: 107-15.
Kairemo K, Erba P, Bergstrom K, Pauwels EKJ. Nanoparticles in Cancer. Curr Radiopharmaceu 2008; 1: 30-36.
Lee ES, Kim D, Youn YS, Oh KT, Bae YH. A virus-mimetic. Angew Chem Int Ed 2008; 47: 2418-21. http://dx.doi.org/10.1002/anie.200704121
Lee ES, Youn YS. Synthesis and Evaluation. Bull Korean Chem Soc 2008; 29(8): 1539-44.
Besic E. Physical mechanisms. Acta Pharm 2007; 57: 249-68.
Iessi E, Marino ML, Lozupone F, Fais S, Milito AD. Tumor acidity. Cancer Therapy 2008; 6: 55-66.
Kamada H, Tsutsumi Y, Yoshioka Y, et al. Design of a pH-Sensitive. Cancer Res 2004; 10: 2545-50. http://dx.doi.org/10.1158/1078-0432.CCR-03-0544
Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K. Preparation and biological. Bioconjug Chem 2005; 16: 122-30. http://dx.doi.org/10.1021/bc0498166
Wei H, Zhang XZ, Chen WQ, Cheng SX, Zhuo RX. Self-assembled J Biomed Mater Res A 2007; 83: 980-89. http://dx.doi.org/10.1002/jbm.a.31295
Hauck ML, LaRue SM, Petros WP, et al. Phase I trial. Clin Cancer Res 2006; 12(13): 4004-10. http://dx.doi.org/10.1158/1078-0432.CCR-06-0226
Sharma R, Chen CJ. J Nanoparticle Res 2009; 11(3): 671-89. http://dx.doi.org/10.1007/s11051-008-9548-z
Ponce AM, Vujaskovic Z, Yuan F, Needham D, Dewhirst MW. Hyperthermia mediated. Int J Hyperthermia 2006; 22: 205-13. http://dx.doi.org/10.1080/02656730600582956
Dreher MR, Liu W, Michelich CR, Dewhirst MW, Chilkoti A. Thermal Cycling. Cancer Res 2007; 67(9): 4418-24. http://dx.doi.org/10.1158/0008-5472.CAN-06-4444
Bordan MA, Sarantos MR, Stieger SM, Simon SI, Ferrara KW, Dayton PA. Ultrasound radiation. Mol Imaging 2006; 5(3): 139-47.
Blanco E, Kessinger CW, Sumer BD, Gao J. Multifunctional micellar. Exp Biol Med 2009; 234: 123-31. http://dx.doi.org/10.3181/0808-MR-250
Howard B, Gao A, Lee SW, Seo MH, Rapoport N. Ultrasound-enhanced. Am J Drug Deliv 2006; 4: 97-104. http://dx.doi.org/10.2165/00137696-200604020-00005
Jufferman LJM, Meijering BDM, van Wamel A, et al. Ultrasound and microbubble-targeted. Neth Heart J 2009; 17: 82-6.
Mykhaylyk O, Cherchenko A, Ilkin A, et al. Glial brain tumor. J Magn Mag Mater 2001; 225: 241-47. http://dx.doi.org/10.1016/S0304-8853(00)01264-6
Hans ML, Lowman AM. Biodegradable nanoparticles. Curr Opin Solid State Mater Sci 2002; 6: 319-27. http://dx.doi.org/10.1016/S1359-0286(02)00117-1
Jordan A, Scholz R, Maier-Hauff K, et al. Presentation of a new. J Magn Magn Mater 2001; 225: 118-26. http://dx.doi.org/10.1016/S0304-8853(00)01239-7
Kumar CS, Leuschner C, Doomes EE, Henry L, Juban M, Hormes J. Efficacy of lytic. J Nanosci Nanotechnol 2004; 4(3): 245-49.
Kim KS, Park JK. Magnetic force. Lab Chip 2005; 5(6): 657- 64.
Lübbe AS, Alexiou C, Bergemann C. Clinical Applications. J Surg Res 2001; 95(2): 200-06.
Sakhnini L, Khuzaie R. Magnetic behavior. Eur Biophys J 2001; 30: 467-70. http://dx.doi.org/10.1007/s002490100171
Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T. Targeted systemic. Int J Oncol 2001; 18(1): 121-5.
Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T. Targeted delivery. Int J Oncol 2000; 17(2): 309-15.
Liu TY, Hu SH, Liu KH, Shaiu RS, Liu DM, Chen SY. Instantaneous Drug. Langmuir 2008; 24: 13306-11. http://dx.doi.org/10.1021/la801451v
Jordan A, Scholz R, Wust P, Hling HF, Felix R. Magnetic fluid. J Magn Magn Mater 1999; 201: 413-19. http://dx.doi.org/10.1016/S0304-8853(99)00088-8
Wang SH, Shi X, Van Antwerp M, et al. Dendrimer-Functionalized. Cells Adv Funt Mater 2007; 17: 3043-50. http://dx.doi.org/10.1002/adfm.200601139
Gonzales M, Krishnan KM. Synthesis of magnetoliposomes. J Magn Magn Mater 2005; 293(1): 265-70. http://dx.doi.org/10.1016/j.jmmm.2005.02.020
Neilsen OS, Horsman M, Overgaard J. A future for hyperthermia. Eur J Cancer 2001: 37: 1587-9. http://dx.doi.org/10.1016/S0959-8049(01)00193-9
Lok C. Picture perfect. Nature 2001; 412: 372-4. http://dx.doi.org/10.1038/35086702
Halavaara J, Tervahartiala P, Isonieme H, Hockerstedt K. Efficacy of sequential. Acta Radiologica 2002; 43: 180-5. http://dx.doi.org/10.1080/028418502127347727
Brazel CS, Johnson DT, Nikles DE, Kim DH. Heat generation. J Magn Magn Mater 2008; 320: 2390-6.
Huang S, Yang P, Cheng Z, et al. Synthesis and Characterization. J Phys Chem C2008; 112(18): 7130-37. http://dx.doi.org/10.1021/jp800363s
Jain TK, Morales MA, Sahoo SK, Leslipelecky DL, Labhasetwar V. Iron Oxide. Mol Pharmaceutics 2005; 2(3): 194-205. http://dx.doi.org/10.1021/mp0500014
Jenny Y. Chien, Rodney J.Y. Ho. Drug delivery trends. J Pharmaceutl Sci 2008; 97: 2543-47.
Rodney J.Y. Ho, Jenny Y. Chien. Drug delivery trends. J Pharmaceutl Sci 2009; 98: 1928-34.
Furra BJA, Hutchinsonb FG. A biodegradable delivery. J Controll Rel 1992; 21: 117-27. http://dx.doi.org/10.1016/0168-3659(92)90013-H
Sankaram MB. Sustained-Release. Florida: Interpharm/CRC Publication, 2000.
Mansel R, Goyal A, Preece P, et al. European randomized. Am J Obstet Gynecol 2004; 191: 1942-49. http://dx.doi.org/10.1016/j.ajog.2004.06.100
http://www.medilexicon.com/drugs/lupron_depot_293.php. Lupron Depot. vol. 2009, 1997.
Sotiriou GA, Hirt AM, Lozach PY, Teleki A, Krumeich F, Pratsinis SE. Hybrid, silica-coated. Chem Mater 2011; 23: 1985-92. http://dx.doi.org/10.1021/cm200399t
Garland J, Buscombe JR, Bouvier C, et al. Sandostatin LAR (long-acting octreotide acetate). Alimentary Pharmaco Therapeut 2003; 17: 437-44. http://dx.doi.org/10.1046/j.1365-2036.2003.01420.x
Xiang S, Keates AC, Fruehauf J, et al. In vitro and in vivo. Mol Biol 2009; 487: 147-160.
Nguyen TA, Fruehauf JH. Transkingdom RNA. Methods Mol Biol 2009; 514: 27-34. http://dx.doi.org/10.1007/978-1-60327-527-9_3
Downloads
Published
How to Cite
Issue
Section
